Shots:

• The companies collaborated to develop companion diagnostic utilizing Thermo Fisher’s Oncomine Dx Target Test for the identification of RET-altered NSCLC and thyroid cancer patients who may be treated with Lilly’s LOXO-292
• Thermo Fisher will retain rights to commercialize its test in all markets including the US- EU and Japan. Post validation- Thermo Fisher will submit sPMA to the US FDA to widen clinical use of its Oncomine Dx Target Test
• LOXO-292 is an oral RET inhibitor being evaluated in P-I/II study for advance cancers harboring RET alterations. Oncomine Dx Target Test is a next-generation sequencing-based test- approved in the US FDA in 2017 and approved for reimbursement by MHLW in Japan

Click here to­ read full press release/ article

Ref: Thermo Fisher | Image: Eli Lilly